In this webinar, Linda Randall, PhD, AVP of Biologics Development, Manufacturing and Control at Pharmaron, focuses on advancing the development of biological drugs from discovery through to commercial supply.
With expertise in both microbial and mammalian expression systems, the key steps from discovery to candidate selection are outlined. Learn how to move effectively from discovery to candidate selection, and explore the steps required to complete the IND-enabling phase of product development. The session also covers the preparation needed for BLA and MAA submissions, ensuring the requirements for successful regulatory approval are met.
Key Topics Include:
- Navigating discovery to candidate selection efficiently
- Completing the IND-enabling phase for product success
- Preparing for BLA and MAA submissions to achieve regulatory approval
- Categories: Clinical Research, Drug Discovery & Development, Pharmacology, Toxicology
- Tags: biopharmaceutical, chemistry, Clinical Applications, clinical research, drug development, drug discovery, drug manufacturing, drug safety, drug screening, IND, regulatory compliance, safety pharmacology
Presenters
Linda Randall, PhD
Associate Vice President
Biologics Development, Manufacturing and Control
Pharmaron
Dr. Linda Randall is Associate Vice President of Biologics Development, Manufacturing and Control at Pharmaron.
Production Partner
Pharmaron, Inc
Pharmaron is a premier life science service provider offering comprehensive research, development, and manufacturing service capabilities throughout the drug discovery, preclinical, clinical development, and commercialization process for small molecules, biologics, and CGT products.
Additional Content From Scientist.com
How to Avoid Expensive Redesign Cycles in Antibody Discovery
Learn how integrated antibody discovery and engineering strategies can accelerate the path from hit to optimized lead in less than 12 months while minimizing costly redesign cycles.
Beyond Exposure: Integrating PK/PD for Translational Predictive Power
Learn to integrate PK/PD modeling and strategic biomarkers to bridge the translational gap. Improve clinical predictability for NCEs, ADCs, and large molecules in this technical webinar.
Advancing the Manufacture of Mesenchymal Stromal Cells and Derived Extracellular Vesicles in Stirred-Tank Bioreactors Through Enhanced Bioprocess Control
Learn how to scale the production of MSCs and extracellular vesicles using bioreactor control and real-time monitoring for more consistent therapies.
Related Content
From Clinical Data to Actionable Assets for Pharmaceutical R&D
In this webinar, learn to transform raw clinical and biobanking data into research-ready assets to accelerate pharmaceutical R&D.
Improving Preclinical Decision-Making in Obesity and CKD with Translational In Vivo Phenotyping
Join us to learn how in-depth in vivo phenotyping using patient-relevant models can improve preclinical decision-making.
